At ASH 2025, Fulcrum presented promising data on a sickle cell pill and Incyte is pioneering a new way to treat myelofibrosis ...
Incyte's data bolster efforts to develop a new type of drug for myelofibrosis, and suggest it may be a replacement for Jakafi ...
Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...
A higher dose of the experimental pill for sickle cell disease showed more promise, Fulcrum said at the American Society of ...
A new report looks at Chinese biotech innovation capturing the attention of pharmaceutical executives and investors worldwide ...
The Advisory Committee on Immunization Practices' (ACIP) meetings used to be a geek’s dream: hours of long, maybe dreary ...
At the end of a tense year for science, the American Society of Hematology heard promising data on acute myeloid leukemia, ...
The CDC's ACIP panel voted to recommend delaying the birth dose of the hepatitis B vaccine, ending a policy that has reined ...
John Quackenbush built a lab that is at the forefront of human genetics research and bioinformatics. Trump administration ...
WASHINGTON — Federal vaccine advisers, through a freewheeling, and at times combative two-day meeting, recommended a major ...
A panel that issues advice on U.S. vaccine policy appears prepared to vote to recommend a delay in when most babies begin to ...
Trump has "shaken the hell" out of the 80-year research pact between the government and universities. What now?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results